Search - tctmd.com

Displaying 541 - 560 of 692

Sort: Relevancy | Date

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Presenter: Dean J. Kereiakes, Pieter C. Smits, Lisette Okkels Jensen

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Atherectomy

Presenter: Schuyler Jones, Misti Malone, Brad Martinsen, PhD

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Drug-Coated Balloons

Presenter: Schuyler Jones, Misti Malone, George Papandreou

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

Presentation

Representation of Patients With Kidney Disease in Trials of CVD Interventions

Presenter: Ioannis Konstantinidis

December 02, 2015

Presentation

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

Presenter: Gregg W. Stone

November 23, 2015

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

Advertisement

Levels of Evidence: Single-center vs Multicenter Trials

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Overview of the Clinical Trials for Atherectomy

Overview of the Clinical Trials for Drug-Coated Balloons

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Representation of Patients With Kidney Disease in Trials of CVD Interventions

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content